
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group is a promising investment due to their innovative and revolutionary product, the Organ Care System. With a strong focus on expanding their operations in Europe and the potential for growth in their OCS Kidney program, the company is well-positioned for continued success. Additionally, their core liver franchise and aviation sector show strong performance, and the company is projected to see significant revenue growth in the coming years. Overall, TransMedics' focus on differentiated clinical outcomes and superior logistics make it a strong choice for potential investors.
Bears say
TransMedics Group is currently facing a variety of challenges that may have a negative impact on its stock performance. This includes the historically slow market growth during Q4, weak donor activity at the beginning of 2026, and the potential disruption from CMS' OPO modernization initiatives in the second half of the year. Furthermore, while the company has developed a strong product portfolio with the OCS, ENHANCE Part B, DENOVO, CHOPS, OCS kidney, and international expansion, the success and adoption of these initiatives are not guaranteed and may not have a significant impact on the company's financials until 2027. Additionally, the company's recent increase in operating expenses and its decision to exercise a $375M purchase option for its new HQ may also have a negative impact on its profitability in the near term. Overall, these factors may lead to slower revenue growth and less enthusiastic market sentiment in the coming months, making it difficult for TransMedics Group to meet its revenue and margin targets.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares